贵州伊诺其尼科技

Guizhou Inochini Technology is a biotechnology company based in China that focuses on the discovery and development of innovative small molecule drugs through targeted protein degradation (TPD). The company utilizes its proprietary PROTAC (Proteolysis Targeting Chimera) platform to develop therapies for cancer and other serious diseases. Its research pipeline includes programs targeting the androgen receptor for the treatment of prostate cancer and Bruton's tyrosine kinase for B-cell malignancies. By leveraging TPD technology, Inochini aims to overcome drug resistance and target proteins that are difficult to inhibit with traditional small molecules. The company is positioned as an emerging player in the Chinese innovative drug landscape, focusing on high-value therapeutic targets.